Real-World Study of anti-PD-1 Combined with Regorafenib and Raltitrexed as Third-Line Therapy in Colorectal Cancer.
APA
Yu Y, Li L, et al. (2026). Real-World Study of anti-PD-1 Combined with Regorafenib and Raltitrexed as Third-Line Therapy in Colorectal Cancer.. Journal of gastrointestinal cancer, 57(1). https://doi.org/10.1007/s12029-026-01460-8
MLA
Yu Y, et al.. "Real-World Study of anti-PD-1 Combined with Regorafenib and Raltitrexed as Third-Line Therapy in Colorectal Cancer.." Journal of gastrointestinal cancer, vol. 57, no. 1, 2026.
PMID
41961332
같은 제1저자의 인용 많은 논문 (5)
- Cross-kingdom miRNA delivery by Panax notoginseng-derived extracellular-like nanoparticles vesicles restores neuronal function after ischemic injury.
- Mycosis fungoides.
- Huang-qin decoction increases the sensitivity of EGFR-TKIs to NSCLC cells by regulating stat3/GPX4 to induce redox ratio and ROS to inhibit CSCs.
- A boronate affinity-enhanced and PEGylated cell-imprinted platform for efficient capture of circulating colorectal cancer cells.
- Synergistic Strategies in Systemic Therapy for Advanced Hepatocellular Carcinoma.